CSPC Pharmaceutical Group Limited
CSPCY · OTC
12/31/2024 | 12/31/2023 | 12/31/2022 | 12/31/2021 | |
|---|---|---|---|---|
| Revenue | $30,868 | $34,599 | $35,012 | $34,188 |
| % Growth | -10.8% | -1.2% | 2.4% | – |
| Cost of Goods Sold | $9,269 | $10,202 | $8,864 | $8,113 |
| Gross Profit | $21,599 | $24,397 | $22,726 | $25,472 |
| % Margin | 70% | 70.5% | 64.9% | 74.5% |
| R&D Expenses | $5,523 | $5,338 | $4,579 | $4,215 |
| G&A Expenses | $1,149 | $1,309 | $1,327 | $1,239 |
| SG&A Expenses | $10,366 | $11,365 | $13,027 | $14,051 |
| Sales & Mktg Exp. | $9,217 | $10,056 | $11,699 | $12,812 |
| Other Operating Expenses | $0 | $15 | $0 | $0 |
| Operating Expenses | $15,889 | $16,717 | $17,605 | $18,266 |
| Operating Income | $5,710 | $7,680 | $7,583 | $7,663 |
| % Margin | 18.5% | 22.2% | 21.7% | 22.4% |
| Other Income/Exp. Net | $226 | -$291 | $998 | $737 |
| Pre-Tax Income | $5,936 | $7,389 | $8,581 | $8,400 |
| Tax Expense | $1,319 | $1,317 | $1,350 | $1,422 |
| Net Income | $4,605 | $5,873 | $6,894 | $6,877 |
| % Margin | 14.9% | 17% | 19.7% | 20.1% |
| EPS | 1.56 | 2 | 2.04 | 1.88 |
| % Growth | -22% | -2% | 8.5% | – |
| EPS Diluted | 1.56 | 2 | 2.04 | 1.88 |
| Weighted Avg Shares Out | 2,935 | 2,968 | 2,979 | 2,988 |
| Weighted Avg Shares Out Dil | 2,935 | 2,968 | 2,980 | 2,988 |
| Supplemental Information | – | – | – | – |
| Interest Income | $0 | $0 | $0 | $0 |
| Interest Expense | $44 | $26 | $25 | $8 |
| Depreciation & Amortization | $1,155 | $1,117 | $1,048 | $1,041 |
| EBITDA | $6,865 | $8,533 | $8,655 | $9,275 |
| % Margin | 22.2% | 24.7% | 24.7% | 27.1% |